Aqueduct Neurosciences, Inc. was founded with the mission to improve the treatment of neurological disorders related to the production and regulation of cerebral spinal fluid (CSF). It was cofounded by Neurological Surgery Associate Professor Samuel Browd, who serves as its Chief Medical Officer and Director.  It offers implantable shunts for the treatment of hydrocephalus, as well as provides an electro-mechanical technology platform that advances the control of draining CSF and minimizes the frequent causes of mechanical failure of the shunt devices. The company also provides an external CSF drainage system that regulates elevated intracranial pressure without the need for manual measurements, adjustments, and interventions, as well as prevents acute hydrocephalus and other conditions, such as traumatic brain injury, tumors, and infections.